BioXcel Therapeutics, Inc. financial data

Symbol
BTAI on Nasdaq
Industry
Pharmaceutical Preparations
Location
555 Long Wharf Drive, New Haven, CT
State of incorporation
DE
Fiscal year end
December 31
Latest financial report
10-Q - Q3 2024 - Nov 14, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 238 % -47.7%
Quick Ratio 7.74 % +33.4%
Debt-to-equity -194 % -135%
Return On Equity 98.3 %
Return On Assets -105 % +22.3%
Operating Margin -3.37K %

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 42.7M shares +46%
Common Stock, Shares, Outstanding 42.5M shares +45.1%
Entity Public Float 135M USD -46.2%
Common Stock, Value, Issued 42K USD +44.8%
Weighted Average Number of Shares Outstanding, Basic 42.4M shares +44.8%
Weighted Average Number of Shares Outstanding, Diluted 42.4M shares +44.8%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 2.28M USD -37.2%
Research and Development Expense 34.5M USD -67.8%
General and Administrative Expense 55.5M USD +66.6%
Costs and Expenses 78.9M USD -61.7%
Operating Income (Loss) -76.6M USD +62.6%
Nonoperating Income (Expense) 62K USD
Net Income (Loss) Attributable to Parent -71M USD +66.4%
Earnings Per Share, Basic -2.16 USD/shares +70.6%
Earnings Per Share, Diluted -2.16 USD/shares +70.6%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 40.4M USD -55.1%
Inventory, Net 1.53M USD -24.4%
Other Assets, Current 1.4M USD -35.6%
Assets, Current 47.8M USD -51.6%
Property, Plant and Equipment, Net 552K USD -36%
Operating Lease, Right-of-Use Asset 461K USD -39.5%
Other Assets, Noncurrent 87K USD 0%
Assets 48.9M USD -51.3%
Accounts Payable, Current 14.9M USD +39.6%
Employee-related Liabilities, Current 39K USD -99%
Accrued Liabilities, Current 10.2M USD -61.7%
Liabilities, Current 25.6M USD -35.1%
Operating Lease, Liability, Noncurrent 161K USD -69.6%
Liabilities 135M USD -4.63%
Retained Earnings (Accumulated Deficit) -639M USD -12.5%
Stockholders' Equity Attributable to Parent -85.6M USD -111%
Liabilities and Equity 48.9M USD -51.3%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -17.7M USD +66.2%
Net Cash Provided by (Used in) Financing Activities 26.6M USD +10.3%
Net Cash Provided by (Used in) Investing Activities -120K USD +62%
Common Stock, Shares Authorized 200M shares +100%
Common Stock, Shares, Issued 42.5M shares +45.1%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 8.92M USD
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 40.4M USD -55.1%
Deferred Tax Assets, Valuation Allowance 174M USD +46.7%
Operating Lease, Liability 529K USD -39.1%
Depreciation 310K USD -3.43%
Payments to Acquire Property, Plant, and Equipment 120K USD -62%
Lessee, Operating Lease, Liability, to be Paid 551K USD -40.8%
Property, Plant and Equipment, Gross 1.98M USD 0%
Operating Lease, Liability, Current 368K USD +8.56%
Lessee, Operating Lease, Liability, to be Paid, Year Two 65K USD -83.4%
Lessee, Operating Lease, Liability, to be Paid, Year One 391K USD +2.63%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 22K USD -64.5%
Lessee, Operating Lease, Liability, to be Paid, Year Three 65K USD -83.4%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10M shares 0%
Unrecognized Tax Benefits 0 USD
Lessee, Operating Lease, Liability, to be Paid, Year Four 65K USD -83.4%
Additional Paid in Capital 554M USD +4.92%
Preferred Stock, Shares Outstanding 0 shares
Depreciation, Depletion and Amortization 309K USD +50%
Deferred Tax Assets, Net of Valuation Allowance 197K USD -23%
Share-based Payment Arrangement, Expense 9.95M USD -49.1%
Interest Expense 13.6M USD +17.1%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%